17 results about "CD24" patented technology

Disclosed are a CD24 antibody or an antigen-binding fragment thereof and the medical use thereof. Further, disclosed are a chimeric antibody comprising CDRs of the CD24 antibody, a humanized antibody, a pharmaceutical composition comprising the CD24 antibody or the antigen-binding fragment thereof, and the use thereof as an anticancer drug.

The invention discloses a bispecific antibody coupling drug targeting CD24 and HER2 and a preparation method and application thereof.The bispecific antibody coupling drug comprises an anti-CD24 heavy chain, an anti-CD24 light chain, an anti-HER2 heavy chain, an anti-HER2 light chain, a tetrapeptide linker and a topoisomerase I inhibitor exatan derivative, the DAR value of the bispecific antibody coupling drug is 9.25, and the anti-CD24 heavy chain, the anti-HER2 light chain, the tetrapeptide linker and the topoisomerase I inhibitor exatan derivative are different. The compound has strong cytotoxicity and internalization ability on breast cancer cells, not only can specifically target tumor tissues, but also can release drugs to kill target cells and adjacent tumor cells, and can significantly inhibit growth of breast cancer tumors. An antibody part DACH023 in the bispecific antibody coupling medicine is the same as a traditional IgG molecule, a traditional monoclonal antibody structure is reserved to the maximum extent, due to the existence of an Fc fragment, a common Protein A column affinity chromatography method can be adopted for purification, and large-scale production and purification are facilitated.

The application discloses humanized anti-CD24 antibodies and application thereof, relates to the technical field of biological medicine, and specifically provides humanized antibodies capable of specifically recognizing CD24 and application thereof. FR regions and constant regions of a mouse-derived anti-CD24 monoclonal antibody are replaced by human-derived FR regions and constant regions, and CDR of the variable region of the mouse-derived anti-CD24 monoclonal antibody is retained, so that a series of anti-CD24 humanized monoclonal antibodies are obtained. The humanized antibodies obtained by the application have an affinity to CD24 antigens which is basically equivalent to that of a human-mouse chimeric anti-CD24 monoclonal antibody WT, and exhibit strong anti-tumor capacity in vivo.

The invention discloses an inflammatory bowel disease treatment method based on intestinal flora regulatory gene CD24 expression. According to the method, expression or functions of CD24 in host intestinal epithelial cells are up-regulated, the intestinal flora structure is adjusted, and intestinal inflammation is relieved. CD24 up-regulation can be realized by transfecting a CD24 gene overexpression vector, applying a transcription factor or a small molecule agonist or enhancing the activity of an endogenous gene by utilizing a gene editing technology. The CD24 is regulated and controlled, so that the proportion of the phylum firmicalis to the phylum bacteroides can be normalized, the enrichment of short-chain fatty acid producing flora is promoted, the activation of NF-kappa B and NLRP3 inflammasomes is inhibited, and the intestinal barrier function is enhanced. The DSS induced colitis model is established by drinking a 2-5% dextran sodium sulfate solution by a mouse, and simulates the pathological characteristics of human ulcerative colitis. Intervention modes include oral administration, enema or nanoparticle targeted delivery of the CD24 agonist pharmaceutical composition. The invention provides a new strategy for the treatment of inflammatory bowel diseases, especially ulcerative colitis, and has obvious dual curative effects of anti-inflammation and flora regulation.

A group of CD24-binding proteins and their uses are provided. Specifically, a group of antigen-binding proteins is provided in which cells expressing the antigen-binding protein may have cytotoxicity and safety. The use of antigen-binding proteins in the preparation of pharmaceuticals is also provided.

This invention relates to the application of targeting the ABHD17C-BCL6B-CD24 signaling axis in the preparation of pancreatic cancer treatment products, the products comprising diagnostic reagents and targeted drugs. The diagnostic reagent kit contains at least one of the following: a reagent for detecting ABHD17C, a reagent for detecting BCL6B expression, and a reagent for detecting CD24 expression. The targeted drug for improving the efficacy and prognosis of pancreatic cancer treatment contains at least one of the following: a reagent for inhibiting ABHD17C expression, a reagent for inhibiting BCL6B expression, and a reagent for inhibiting CD24 expression. This invention reveals the mechanism by which the ABHD17C-BCL6B-CD24 signaling axis regulates pancreatic cancer, providing a theoretical basis for the precise diagnosis and targeted therapy of pancreatic cancer, and has broad clinical application prospects.

Provided herein are antibody-drug conjugates containing an anti-CD24 antibody conjugated to a cytotoxic agent via a linker, in which the antibody selectively binds to human CD24 protein expressed on cancer cells but not human CD24 expressed in non-cancerous cells; and uses thereof for treating cancer.

The application discloses a VirusTAC platform for tumor cell membrane protein PD-L1 or CD24 targeted degradation and application thereof, and belongs to the technical field of biological medicine. The platform comprises a heterodimer with R1-R2-R3 structure formed by a first polypeptide chain and a second polypeptide chain, wherein R1 is MeV H or a variant thereof; R2 is a linker composed of R4 and R5, R4 is an IgG Fc region; R5 is a linker that can be cut by a protease; and R3 is a target protein binding domain PD-L1 antibody or CD24 antibody. The platform can specifically recognize tumor high-expression receptors and induce rapid endocytosis of cells by means of tumor-specific expression and efficient endocytosis characteristics of Nectin-4, so as to overcome the defects of the existing TPD technology and realize effective regulation of various target proteins.

The application provides an enzyme-responsive peptide-based nucleic acid targeting delivery system and a preparation method and application thereof, and relates to the technical field of biotechnology.The delivery system comprises nanomicelles and CD44-targeting nucleic acid aptamers connected to the outer layer of the nanomicelles; the nanomicelles are composed of enzyme-responsive peptides and CD24 siRNA adsorbed to the enzyme-responsive peptides; the enzyme-responsive peptide is a hydrophobic functional group-CGGFLG-HHHKKHHHKKK; and the CD24 siRNA targets and silences a CD24 gene.The delivery system can effectively target triple-negative breast cancer cells, and improves the targeting and drug loading capacity of a targeted drug for triple-negative breast cancer tumors.

The invention discloses an antigen epitope peptide coded by mRNA and fused in phosphatidylinositol anchoring protein and application of the antigen epitope peptide, and belongs to the field of biological medicine. The antigen epitope peptide comprises a MUC1 (1TR)-CD24 molecule and a MUC1 (1TR, 13aa)-CD24 molecule; the MUC1 (1TR)-CD24 molecule comprises an MUC1 signal peptide, an MUC1 extracellular domain containing one MUC1 VNTR sequence, a CD24 polypeptide and a phosphatidylinositol anchoring signal peptide; the MUC1 (1TR, 13aa)-CD24 molecule contains MUC1 signal peptide, MUC1 (1TR, 13aa) sequence, CD24 polypeptide and phosphatidylinositol anchoring signal peptide, the process is simple, the sequence is controllable, CAR-T cell amplification can be efficiently activated, CAR-T cells can be stimulated to secrete anti-tumor cell factors, and the MUC1 (1TR, 13aa)-CD24 molecule has important medical value in preparation of drugs for treating cancers or preventing cancer relapse.

The present invention relates to a novel anti-CD24 antibody and a use thereof, and more particularly, to a novel anti-CD24 antibody and a use thereof, the CD24-specific antibody according to one aspect can increase the phagocytic activity of macrophages in tumor tissues, can be used as a general anticancer agent to effectively prevent or treat various cancers related to CD24, is not limited to cancer species, has high binding affinity to both human and mouse, and can be used clinically and pre-clinically.

The present invention relates to a novel method for the diagnosis, prognosis, stratification and / or therapy monitoring of cancer diseases in patients. The method is based on the determination of CD3+ tumor infiltrating lymphocyte levels and CD24 expression. The novel biomarker combination of the present invention allows the diagnosis, prognosis, stratification and / or therapy monitoring of various cancer diseases. Furthermore, diagnostic kits for performing the non-invasive method of the present invention are provided.

This invention discloses a shuttle peptide targeting YY1S247 phosphorylation and its application. The sequence of the shuttle peptide is shown in SEQ ID NO: 1. RQIKIWFQNRRMKWKK is a part of the Drosophila melanogaster tentacles peptide, used to provide cell penetration; PKKKRKV is the nuclear localization sequence of the SV40 large T antigen, used to guide the peptide into the cell nucleus; QIIGENSPPDYSE is the surrounding sequence of the YY1S247 site. The results show that the shuttle peptide (CPP) of this invention can competitively and specifically inhibit phosphorylation at the YY1S247 site, thereby inhibiting CD24 expression and enhancing the therapeutic effect of EGFR-TKIs.

Provided are a group CD24 binding proteins and uses thereof. Specifically provided is a group of antigen binding proteins, wherein cells expressing the antigen binding protein can have cytotoxicity and safety. Also provided is a use of the antigen binding protein in the preparation of a medication.

The invention discloses a CD24 positive nucleus pulposus progenitor cell for inhibiting nucleus pulposus cell ferroptosis, a pharmaceutical composition and application. The invention firstly protects an isolated CD24 + NPPCs population and a pharmaceutical composition thereof. The invention protects the application of the cell population and the pharmaceutical composition in preparation of drugs for inhibiting nucleus pulposus cell ferroptosis and / or improving intervertebral disc degeneration microenvironment. The nucleus pulposus progenitor cell subgroup is enriched and obtained by taking CD24 as a marker. Experiments prove that the cell population can play a role through a multiple synergistic mechanism: on one hand, the ferroptosis of nucleus pulposus cells is effectively inhibited by up-regulating proteins such as GPX4 and SLC7A11 and reducing lipid peroxidation; on the other hand, by reducing the level of proinflammatory factors such as TNF-alpha and promoting synthesis of extracellular matrixes such as Aggrecan and COL2A1, the healthy intervertebral disc microenvironment is remodeled, and tissue regeneration is promoted.

Provided herein are CD24 binding antibodies, and methods of making and using the same. These antibodies may be useful for the treatment of a disease or condition such as cancer.

The present invention pertains to anti-CD24 antibodies which bind CD24 in an O-glycosylation-dependent manner. Thereby, the antibodies are specific for tumor-associated CD24. The invention further provides pharmaceutical compositions containing said anti-CD24 antibodies and their use in cancer treatment.